Objective To determine the effectiveness of methylphenidate for depression treatment in patients with advanced cancer.
| BACKGROUND
Major depressive disorder can be diagnosed in up to 26% of patients with advanced cancer. [1] [2] [3] Major depressive disorder is associated with shortened survival, suicidality, and increased pain symptoms. 4 Treatment of depression in this patient population is complicated by shortened life expectancy. 1, 5 Conventional antidepressant medications, such as tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs), have a delayed onset of action of up to 8 weeks after initiation. [6] [7] [8] Therefore, many patients with advanced cancer, especially those enrolled in hospice, do not live long enough to benefit from these typical medications.
The potential benefits of methylphenidate in this population are diminished depressive symptoms and initial efficacy within 2 to 3 days of treatment. 9, 10 Adverse effects requiring discontinuation of treatment are reported in less than 10% of patients 11, 12 and promptly resolve with discontinuation of treatment. 13, 14 Psychostimulants may also decrease opioid sedation 15 and improve cognitive function in patients with cancer. 16 Among two small clinical trials of methylphenidate for treatment of depression in patients with advanced cancer, one showed benefit even though only 44% of participants completed the study 12 ; another showed a positive trend. 17 We conducted a randomized, double-blind, placebo-controlled clinical trial of methylphenidate for depression treatment in SSRItreated patients with advanced cancer who were enrolled in hospice or receiving palliative care. The goals of this study were to (i) compare methylphenidate to placebo in the context of ongoing SSRI use for treatment of depression in patients with cancer and (ii) determine the adverse effects of methylphenidate in combination with SSRIs. 
| Outcome measures
The primary endpoint was remission in depression at the end of 18-day treatment period, as determined by a 50% decrease in MADRS score. The MADRS was chosen as the primary depression measure because it minimizes physical symptoms of depression that may artificially inflate depression scores in patients with physical illness.
Both the proportion of patients who had this remission and time to remission were compared between methylphenidate and placebo groups. Secondary endpoints included change in depression scales as measured by HADS and MADRS and overall survival between groups.
| Analysis
The target sample size was 104 patients (52 per group), which would provide 80% power to detect 53% remission rate vs 20%
remission rate between the methylphenidate and placebo groups, respectively. The sample size was based on a two-sample t-test with 5% significance level and accounted for an expected 30% loss due to follow-up, deaths, and withdrawals. Generalized estimating equations (GEE) method 27 was used to assess changes in MADRS depression scores over time in an intention-to-treat analysis. The GEE model offers flexible regression modeling for incomplete repeated Time to remission between the methylphenidate and placebo groups was estimated by the Kaplan-Meier method compared using a log-rank test. All participants were evaluated at the end of 18-day trial with respect to the presence or absence of depression. In this analysis those who were alive but did not go into remission were censored at day 18, and those who died prior to the end of 18-day trial were censored at the time of their death. Wilcoxon rank sum test was used to compare HADS scores between groups.
All analyses accounted for stratification factors: treatment status, SSRI prescribed more than 1 month before study entry, life-prolonging treatment received, and hospice enrollment. P-values less than .05
were considered statistically significant. All analyses were generated using Statistical Analysis System version 9.4.
| RESULTS
A total of 47 participants were enrolled; 12 participants were later excluded as they did not meet inclusion/exclusion criteria at study entry (eg, MADRS score was not high enough, Short Portable Mental Status Questionnaire was too low, or stimulant abuse was found on review of systems). Three additional participants were consented but did not start the study medication: two withdrew and one became ineligible secondary to worsening medical status (Figure 1 ). Among the total sample who received study drug, 78% were men, mean age was 64 years, and the most common types of cancer were colon (38%) and lung (22%). The median number of days from first day of study drug (day 1) until death was 109 days (intra-quartile range, 373 days) in the methylphenidate group and 118 days (intra-quartile, 189 days) in the placebo group ( Figure 2 ).
Using GEE analysis the overall test for linear trend in the MADRS scores combining the two groups revealed a significant decreasing linear trend (P < .001). When restricting the analysis to the MADRS scores in the methylphenidate group, the linear trend test revealed a significant decreasing trend (estimated mean = −1.58; P < .001) that was larger than the observed decreasing trend in the placebo group (estimated mean = −1.05; P < .001). There Wilcoxon rank-sum test) ( Table 2) . After first remission, 1 participant in the methylphenidate group (7%) and 5 participants in the placebo group (29%) experienced a relapse of their depression during the study (P = .18, Fisher's exact).
Ten participants did not complete the trial, including 6 from the methylphenidate group and 4 from the placebo group. Reasons for withdrawal from the methylphenidate group included death (n = 1), elevated blood pressure (n = 1), delirium (n = 2), nausea (n = 1), and patient decision to stop the trial unrelated to adverse effects (n = 1). Among the placebotreated patients, withdrawal occurred because of death (n = 1), elevated blood pressure (n = 1), dizziness (n = 1), and intolerance of citalopram (n = 1) (Supplemental Table 1 ). There was no difference in mortality between groups during the 18-day trial period. At final data analysis completed 12 months after the conclusion of the trial, 80% of the methylphenidate group and 88% of the placebo group were deceased.
| CONCLUSIONS
In this trial we failed to show that among SSRI-treated patients with advanced cancer, who were enrolled in hospice or receiving palliative care, methylphenidate has a significant effect on depression remission compared with placebo. Patients in the methylphenidate group did, however, appear less likely to experience a relapse of their depression once in remission compared with patients in the placebo group, although not statistically significant. There was no mortality difference between groups during the trial. Trial results were limited by small sample size attributed to difficulties in recruiting patients from this very ill population. There was both an unexpectedly high response rate among subjects in the placebo group and considerable variability in depression scores over time, which impacted our ability to detect differences between groups. By day 6 of the study, 69% of the placebo group was in remission, suggesting that an even larger sample size than the original analytic approach may not have been able to demonstrate a statistical difference. Our study underscores the difficulties in conducting ran- were not required for inclusion. In the two studies methylphenidate had no effect on depressive symptoms. 29, 30 In a third study of fatigue focused on hospice patients, methylphenidate had significant benefit on all depression measures among a subset of patients with clinically significant depression.
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Our study did suggest a potential benefit of treatment with methylphenidate among depressed terminally ill cancer patients in reducing the depression relapse rate. Although not statistically significant, patients taking methylphenidate appear less likely to experience a relapse of their depression than patients in the placebo group within the 18-day study period. It is unclear if this represents a potential additional benefit of adjunctive methylphenidate use in these patients or if the variability in depression scores impacted the observed relapse rate differences between groups. A prospective study of mental disorders in Veterans enrolled in hospice at the VA Portland Health
Care System found that patients have high variability from day to day and week to week in their depression scores. 31 Another study in prostate cancer patients found similar depression variability. 32 In this patient population the variability in depression scores should be considered in future trial designs.
We encountered a variety of barriers in conducting this trial, and further discussion may prove valuable for future investigators attempting such research. Some barriers were foreseen, but attempts to mitigate the barriers had unanticipated effects. For example, among patients with shortened life expectancy, nontreatment of depression was deemed unethical and thought likely to negatively impact recruitment. Therefore, all participants received an SSRI. We reasoned that, with both arms receiving some type of depression treatment study, participation would increase, but also reasoned it was likely that over 18 days, any improvement attributable to SSRIs would be negligible.
As such, the SSRI was considered an "active placebo." It is possible, however, that SSRI treatment contributed to the high placebo response. Even with a study design in which all patients received depression treatment, the study was closed for several months after continuing review by the OHSU Institutional Review Board when a new IRB Chair questioned whether it was ever ethical to enroll terminally ill patients into research studies. Shortened life expectancy also precluded the use of a "run-in" study design that could have assured depression persistence before starting treatment, potentially decreasing the placebo response. Another anticipated barrier in trial design was the added burden to hospice patients coming to the hospital for study visits. The social benefits of home visits from study psychologists, however, may have contributed to the high placebo response rate, undermining the trial's ability to demonstrate a positive effect of methylphenidate. Despite these study accommodations, only half of the planned recruitment was achieved before project funds were expended.
Other barriers were unanticipated. For example, we experienced difficulty engaging oncologists in screening patients at the OHSU site.
Some oncologists admitted they did not want to ask their patients if they were feeling sad or depressed because they were limited in accessing mental health referral for patients who did not enroll in the study. A second unanticipated barrier was secular changes in hospice enrollment from study planning to the beginning of recruitment wherein length of stay preceding death for patients with cancer at the largest participating hospice program declined from 17 to 12 days.
Therefore, many hospice patients were too ill to be considered for enrollment, and we expanded study eligibility to nonhospice patients.
These barriers highlight the difficulties in conducting research in patients with shortened life expectancies. 
